Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cidofovir injection

- PMLiVE

Gilead lead NASH drug flunks phase 3 test

Analysts suspect the setback could prompt Gilead to license other candidates

- PMLiVE

Gilead awaits CEO and readouts to revive fortunes

NASH and oral RA drugs set for crucial readouts

- PMLiVE

CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL

Novartis agrees pricing deal with NHS England

- PMLiVE

Roche’s O’Day swaps big pharma for big biotech

Move to Gilead enforces reshuffle at neighbours Genentech

- PMLiVE

Gilead NASH drug clears mid-stage trial, but rivals are looming

Positive results to challenge Intercept in emerging disease area

- PMLiVE

Gilead and Galapagos JAK contender scores in RA trial

Trial adds to rivalry with AbbVie

- PMLiVE

Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership team

The latest industry movers

Gilead Sciences

Gilead, Galapagos JAK inhibitor clears phase II test

Hopes to compete with already-marketed drugs from Pfizer and Eli Lilly

- PMLiVE

Novartis and Gilead rival CAR-Ts approved in Europe, but supply capacity in question

Gilead looks to have edge in crucial manufacturing capability

- PMLiVE

Daily Brief: another departure at Gilead, veteran researcher to head up Karuna

Exodus continues from Gilead

- PMLiVE

Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down

News from pharma, biotech and healthcare

- PMLiVE

GSK two-drug trial in untreated HIV raises Gilead rivalry

Intends to file the combination later this year to challenge Gilead’s Biktarvy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links